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Abstract 
 
Background:  
Pregnant women with Inflammatory Bowel Disease (IBD) are at increased risk of adverse 
pregnancy outcomes. Comprehensive guidelines on medical management have been published 
yet there is limited guidance on service set-up and minimum standards of care for pregnant 
women with IBD. 
Aim:  
To develop a position statement on service set-up and minimum standards of care in the United 
Kingdom.  
Methods:  
A working group consisting of 16 gastroenterologists, obstetricians, obstetric physician, IBD 
specialist nurses and midwives was assembled. Initial draft statements were produced and a 
modified Delphi process with 2 rounds of voting applied. Statements were modified according 
to voters’ feedback after each round. Statements with ≥80% agreement were accepted.  
Results:  
All 15 statements met criteria for inclusion. To facilitate optimal care regular and effective 
communication between IBD and obstetric teams is required. There should be nominated link 
clinicians for IBD in obstetric units and for pregnancy in IBD units. Preconception counselling 
should be available for all women with IBD. All pregnant women should be advised on the 
safety of IBD medication during pregnancy and breast feeding, the optimal mode of delivery, 
the management of biologics (where applicable) and safety of childhood vaccinations. Regular 
audit of pregnancy outcomes and documentation of advice given is recommended. 
 
Conclusion:  
Position statements have been developed that advise on the importance of joined-up 
multidisciplinary care, proactive decision making with clear documentation and communication 
to the woman and other health care practitioners. 
  
Summary Box 
 
What is already known about this subject? 
 IBD affects pregnancy outcomes and requires complex decision making 
 Excellent international guidelines provide advice on medical management 
 
What are the new findings? 
 This position statement provides IBD and obstetric services with guidance on service set 
up and delivery 
 Minimum standards of care have been developed to guide clinicians 
 
How might it impact on clinical practice in the foreseeable future? 
 IBD and obstetric services should review current practice to ensure that standards of 
care are being met 
 Regular audits using the proposed standards can be performed to guide quality 
improvement 
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 Background 
Inflammatory Bowel Disease (IBD) affects many women of child bearing age, who often have 
poor knowledge of pregnancy related issues in IBD,1 views adverse to medical guidelines,2 and 
higher levels of voluntary childlessness.3 4 Women with IBD are at increased risk of adverse 
pregnancy outcomes including pre-term birth, small for gestational age birth weight, 
gestational diabetes, stillbirth and are more likely to have a caesarean section. 5 Over the past 
two decades the management of women with IBD during the reproductive period has evolved 
and comprehensive guidelines have been published by the European Crohns and Colitis 
Organisation, 6 7 the Canadian Society of Gastroenterology (Toronto consensus), 8 and the 
American Gastroenterology Association. 9 These guidelines address most aspects of care 
including advice on medication, vaccinations, investigations, and mode of delivery. 
 
There is however limited guidance for clinicians on how to set up services to deliver safe and 
effective care for pregnant women with IBD. Women with IBD may encounter a multitude of 
health care professionals from different professional backgrounds including general 
practitioners, midwives, obstetricians, IBD specialist nurses and gastroenterologists during their 
pregnancy. Knowledge of IBD related pregnancy care varies between different medical 
specialties increasing the risk of divergent advice being offered by practioners.10 Furthermore 
obstetric and IBD care occurs not infrequently across different health care organisations 
increasing the difficulties in providing coordinated care. Uncoordinated care could increase 
women’s anxiety about the correct management and risk inappropriate cessation of IBD 
therapy. Poor communication between health care professionals could lead to delays in 
treating flares, delays in closely monitoring fetal health during flares, decisions on mode of 
delivery not taking IBD into account, reduced uptake of breast feeding and risk of inappropriate 
live vaccinations in infants exposed to biologics in utero.  
 
Effective guidance on service set up, clear standards on communication and responsibilities in 
providing advice could help improve the safe provision of antenatal care for women with IBD. 
This position statement aims to provide guidance for clinicians involved in the care of pregnant 
patients with Inflammatory Bowel Disease (IBD). The focus of the position statement is on 
service set up and minimum standards of care as well as audit recommendations.  
  
Methods 
British Society of Gastroenterology (BSG) endorsed guidance statements are significant and 
influential brief statements addressing novel, topical or controversial subjects where it is felt 
that the Society needs to clarify its position and give clear advice where possible to the 
membership.11 BSG endorsed guidance statements are often limited to an expert opinion based 
on the latest best available evidence. 11 This endorsed guidance statement was produced to 
address questions on service set-up, responsibilities of clinicians, minimum standards of care 
and suggestions for audit standards. While many aspects may be applicable to the wider IBD 
community the endorsed guidance statement was developed to specifically address care in the 
National Health Service for women living in  Great Britain and Northern Ireland.  
 
A modified Delphi process with a consensus meeting followed by two rounds of online voting 
and subsequent statement modification was applied. A working group was formed under the 
auspices of the BSG and expert clinicians in the field were identified and invited by two of the 
authors (CPS and TG). The final working group consisted of 6 IBD expert gastroenterologists, 5 
obstetricians, 1 obstetric physician, 3 IBD specialist nurses and 1 midwife. While the majority 
worked in academic teaching hospitals 3 working group members came from District General 
Hospitals providing views of services outside of large academic centres. Themes of care 
provision were identified by the working group members through a narrative literature review 
and a face to face meeting in London in October 2018. The endorsed guidance statement was 
drafted in accordance with the guidance of the British Society of Gastroenterology (BSG) on 
endorsed guidance statements, which in contrast to full guidelines advocates a less stringent 
approach without full systematic literature review and without grading of statements.11 Working 
group members rated their agreement on 5 point Likert scales from 1) totally disagree, 2) 
mostly disagree, 3) neutral, 4) mostly agree to 5) totally agree. Statements were included when 
≥80% voted agree or totally agree. The final endorsed guidance statement was first reviewed 
and approved by the BSG clinical services and standards committee and then reviewed and 
endorsed by the council of the British Maternal and Fetal Medicine Society.  
  
Results 
The face to face meeting was attended by 14 working group members and voting rounds were 
closed after the minimum of 10 votes was reached for each round. All 15 statements reached 
the ≥80% agreement threshold and were included in the endorsed guidance statement.  
 
Domain 1: Set up of services 
Traditionally pregnant patients with IBD were likely to have received separate care from IBD 
and obstetric services with great variation in care and service set up. Due to the complexity of 
caring for pregnant IBD patients the care needs to be coordinated between services and 
provision by staff with relevant experience and expertise of IBD and pregnancy is highly 
desirable. Specific IBD antenatal services can facilitate coordinated high-quality care with 
subsequent good maternal and fetal outcomes 12 Joint consultations may not be feasible for all 
services but can provide the best model of care for communication between teams, providing 
unified patient advice and can reduce the number of total appointments required during a 
pregnancy. This may be out of the scope of some units where the number of pregnant women 
with IBD are insufficient to make the provision of joint clinics feasible. 
Statement 1: 
To facilitate optimal care and joint decision-making, regular and effective communication 
between IBD and obstetric teams is required. As a minimum there should be a nominated 
link clinician for IBD in every obstetric unit and a nominated link clinician for pregnancy in 
every IBD unit. [0% mostly, 90% totally agree] 
Statement 2: 
Specially set-up IBD pregnancy clinics can provide optimal specialised care. This is best 
facilitated by a joint clinic with an obstetric clinician and an IBD clinician present during 
the consultation. [30% mostly, 70% totally agree] 
  
Domain 2: Minimum standards of care 
Many patients have poor knowledge of IBD related issues in pregnancy1 and hold attitudes 
contrary to medical guidelines.2 13 These may in turn lead to poor adherence 14and an increased 
risk of flaring disease during pregnancy. As active disease is associated with adverse pregnancy 
outcomes patients should be medically optimized prior to pregnancy, advised on the 
importance of maintaining remission from IBD and be given general advice on pre-conception 
health (smoking; alcohol, folic acid, etc). Patients who received IBD-specific pre-pregnancy 
counselling experienced better disease control during pregnancy and better pregnancy 
outcomes. 12 
 Statement 3: 
Pre-conception counselling should be available to all women with IBD to optimize 
preconception health. Poor patient knowledge on reproductive issues is associated 
with voluntary childlessness and adverse pregnancy related outcomes. Pro-active 
approaches to pre-conception counseling are considered the gold-standard. [0% 
mostly, 100% totally agree] 
 
Medical management of IBD during pregnancy requires weighing of potential risks of 
medication versus the usually higher risk of active disease. The IBD team is best placed to 
measure disease activity and take disease and treatment history into account. Advice on 
medication issues should be provided by the team with the best experience and knowledge. 
Gastroenterologists and IBD nurses have excellent IBD related pregnancy knowledge. 1 15 
For most women with IBD the IBD service can provide pre-pregnancy counseling but for 
women with other health issues or significant problems during previous pregnancies further 
advice from a maternal medicine obstetrician or an obstetric physician should be sought. Up 
to 40% of pregnancies are not planned and ideally all women with IBD of child bearing age 
should receive at least basic information about IBD, contraception and pregnancy. 
 
Statement 4: 
The IBD team must advise all patients with IBD who are pregnant or considering 
pregnancy on drug safety during conception, pregnancy and the importance of 
maintaining remission. [0% mostly, 100% totally agree] 
 
Women with IBD are at increased risk of adverse pregnancy outcomes and therefore have in 
general above average risk pregnancies. 5 A consultant led clinic should review the patient and 
assess for IBD and non-IBD risk factors to facilitate the most appropriate care and follow-up 
during pregnancy. The initial antenatal assessment should be delivered in a consultant led 
antenatal clinic. The visit should be used to stratify disease and pregnancy risk and provide a 
detailed plan for the antenatal care including as a minimum the timing, setting and modality for 
maternal and fetal surveillance. Routine antenatal care should be provided by midwives and 
obstretricians in line with current national obstetric guidelines. 
 
Statement 5: 
Pregnant women with IBD should be offered consultant led obstetric care. Following 
initial clinic assessment care in different clinical settings may be appropriate. [40% 
mostly, 60% totally agree]  
Statement 6: 
All pregnant women with IBD should be offered IBD specialist care by a consultant or 
IBD nurse with experience in IBD pregnancy care. [0% mostly, 100% totally agree] 
Statement 7: 
The frequency of IBD, obstetric and or joint clinic follow-up should be determined by 
IBD disease activity in the absence of other obstetric concerns. Patients with mild 
disease can be monitored remotely (via “telephone” or “virtual” clinics) but moderate 
to severe disease requires follow-up by IBD, obstetric and/or joint clinics. [20% mostly 
agree, 80% totally agree] 
Management of biologics during pregnancy requires complex decision making to ensure 
optimal patient outcomes. European and North American guidance differ on the question of 
continuation during the 3rd trimester.7-9 Discontinuation of anti-TNF at the end of the 2nd 
trimester leads to lower drug levels in cord blood,16 which was thought to reduce the risk of 
serious infections in the infant.16 A large French study has however shown that women who 
discontinued anti-TNF experienced more flares while no differences in infant infection rates 
were seen between those exposed to 3rd trimester anti-TNF and those not exposed. 17 
Women with IBD need to be advised on risks and benefits of continuing biologics during the 
3rd trimester on an individual basis taking into account their disease and treatment history. 
 
Statement 8: 
All pregnant women receiving biological therapy for IBD need to receive individual 
advice on whether to continue or stop therapy during the 3rd trimester and when to 
restart therapy postpartum.  
 This discussion and the decision need to be clearly documented. 
 All women on biologics need to be counselled on safety aspects for the infant 
including vaccinations and advice on infection-related complications. [0% mostly, 
100% totally agree] 
 
While the majority of women with IBD can have a vaginal delivery, choosing caesarean 
sections is crucial for the subset of women with active perianal disease.7 Women with ileo-
anal pouches have borderline continence and may therefore benefit from caesarean 
sections to reduce the risk of sphincter injury.7 Women with IBD have caesarean sections 
significantly more often than then general population.5 Obstetricians should be advised by 
IBD teams whether an IBD indication for caesarean section is present or whether obstetric 
concerns alone in conjunction with patient wishes should guide the mode of delivery 
decision. Discussion with the surgical team may influence both timing and mode of delivery 
with early elective delivery (38 weeks) being preferable to emergency surgical delivery in 
some women with previous complex surgery. If early delivery is required, antenatal 
corticosteroids may need to be considered, to improve fetal lung maturity. 
 
Statement 9: 
All pregnant women with IBD should be advised on whether their IBD influences the 
mode of delivery 
 A clear recommendation on optimum mode of delivery should be made well in 
advance of the expected delivery date. Considerations need to be made in regard 
to absolute contra-indications for a vaginal delivery. Gold standard is a joint IBD-
obstetric decision.  
 For patients with IPAA or perianal disease a joint approach that may include 
surgical input is required. [0% mostly, 100% totally agree] 
 
Breast feeding conveys many benefits to the infant including optimal nutrition, beneficial 
effects on the immune system and a potential reduction in the risk of developing IBD.7 18 
The amount of biologic agent found in breast milk is likely to be small and unlikely to be 
significantly systemically absorbed by the infant. Therefore breast feeding should normally 
be encouraged.8 Patients require individual advice on the risks and benefits to make 
informed decisions on the choice of infant nutrition.  
 
Statement 10: 
All pregnant women with IBD should be counselled on the benefits of breast feeding 
with specific advice on the suitability of their medical treatment on breast feeding well 
in advance of the expected delivery date and the decision should be documented. [0% 
mostly, 100% totally agree] 
 
 
Child hood vaccinations are important for the infant’s health and the appropriate use of 
vaccinations needs to be based on medical advice. Only biologic agents require an 
adjustment from the routine vaccination schedule as live vaccinations carry potential risks 
and should therefore be delayed. 
 
Statement 11: 
All pregnant women with IBD should be counselled on the safety of vaccinations for 
the newborn. Women on relevant biological drugs should be advised that the infant 
should avoid the rota virus vaccination and that the BCG vaccination should be 
delayed. This should be documented. [0% mostly, 100% totally agree] 
 
Pregnant women with IBD have an increased risk of preterm labour and small for gestation 
birth weight.5 This risk is largely from active inflammation and seems to be much lower in 
women having achieved remission from IBD.5 19 Fetal growth scanning can help 
obstetricians identify and/or monitor high risk patients. Growth scans at 28 and 34 weeks 
gestation may be useful in women with active disease but the benefit of routine scanning in 
the third trimester in women with mild disease or in clinical remission from IBD is unclear. 
 
Statement 12: 
Additional growth scans in the 3rd trimester should be considered for patients with active 
IBD and/or other comorbidities as determined by the supervising obstetrician. [10% 
mostly, 90% totally agree] 
 
Patients with IBD are at increased risk of venous thromboembolism (VTE) during flares and this 
risk is further increased during pregnancy.20 For women with active IBD thromboprophylaxis 
with low molecular weight heparin should be considered. The Royal College of Obstetrics and 
Gynaecology (RCOG) guidelines provide helpful advice that includes all known risk factors for 
VTE.21 
 
Statement 13: 
In patients with active IBD prophylaxis against venous thromboembolism should be 
considered taking into account other risk factors using the RCOG VTE guidelines. [0% 
mostly, 100% totally agree 
 
Continuity of care post-delivery is important for all women with IBD. This particularly busy 
period for new mothers can be challenging. Clear advice on when and how to contact the IBD 
service is vitally important to allow for swift follow-up where needed without burdening new 
mothers with routine appointments when in remission. Some women with UC experience a 
higher risk of post-partum flares8 and should be advised on how to manage this. Furthermore 
women who discontinued biologics need to be advised when to restart these. 
 
Statement 14: 
Prior to delivery women should be advised on the plan for follow-up post partum and 
given contact details for the IBD service. [0% mostly, 100% totally agree] 
  
Domain 3: Audit of services 
Routine capture of pregnancy outcome is advised to help services review their results and allow 
for quality improvement programs. We have proposed four audit standards on decision making 
and documentation that are vital to ensure safe high quality care. We suggest that services 
audit their IBD antenatal care to ensuring minimum standards of care are met. 
 
Statement 15: 
Pregnancy related outcome data should be captured regularly where possible and should 
include: delivery date, mode of delivery, complications and breast feeding status. 
Services should aim to achieve a 90% target for: 
 Documented decision on biological therapy during pregnancy 
 Documented advice on delivery method 
 Documented advice on vaccination for the newborn 
 Documented advice on breast feeding [20% mostly agree, 80% totally agree] 
 
Discussion 
The management of IBD during pregnancy requires complex decision making incorporating 
consideration of maternal and fetal health. For the vast majority of patients the risk of active 
IBD poses a risk that far outweighs any medication risk (except for Methotrexate or Tofacitinib) 
and continuation of maintenance therapy is vital to ensure well controlled IBD which in turn is 
associated with better pregnancy outcomes. 5 7 12 22 Patients however often harbor concerns 
and fears over IBD medications during pregnancy, which increases the risk of non-adherence. 13 
23  
Clinician knowledge varies according to specialty, and advice by clinicians not versed in the 
management of pregnant IBD patients may lead to inappropriate (usually over-cautious) 
medical advice. 10 Furthermore uncoordinated care between obstetric and IBD units may 
increase the risk of the patient perceiving medical advice from the respective units to be 
conflicting. Opportunities to optimize care and instigate tighter monitoring of the pregnancy 
may be missed, which in turn could lead to adverse pregnancy outcomes. In light of this the IBD 
antenatal working group was formed to provide this endorsed guidance statement on service 
standards for the care of pregnant women with IBD. The standards are often based on expert 
opinion as evidence for high quality care was sometimes lacking. This endorsed guidance 
statement does not aim to replicate the excellent medical guidance offered by European and 
North American detailed guidelines, 7-9 but aims to provide practical advice for clinicians in the 
United Kingdom on how to organize services and what should be seen as minimum standards of 
care.  
Collaborative working between obstetric and IBD units is, in the view of the working group, key 
to providing high quality care. A dedicated IBD pregnancy clinic in the Netherlands has shown 
that coordinated care and pre-pregnancy counselling are associated with better maternal and 
fetal outcomes.12 While such specially set up clinics are models for high quality care they are 
resource intensive and may not be justified in smaller IBD units where the patient numbers do 
not justify this set-up. Coordinated working can also occur via nominated link clinicians and 
routine communication after every clinical encounter. This is especially important in Trusts 
where different electronic systems for health records are used in maternity and 
gastroenterology. 
To avoid confusion for patients and general practitioners advice on safety of medications during 
pregnancy, breast feeding and child hood vaccinations should be provided to all pregnant 
women with IBD and clearly documented and communicated. Decisions on mode of delivery 
should be informed by advice from the IBD unit whether there is an IBD indication for a mode 
of delivery.  
In summary, this endorsed guidance statement provides advice on how to organise services for 
pregnant women with IBD and sets minimum standards of care. Further work including 
potentially a nationwide audit is required to assess quality of care for pregnant women with 
IBD. Qualitative research into how women perceive their care would also be important. 
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